Scientific Research
Effect of Fufang Danshen Diwan combined with clopidogrel in treatment of outpatients with coronary heart disease
Liu Ning, Jiang Lihua, Yin Chenghua
Published 2023-05-15
Cite as IMHGN, 2023, 29(10): 1392-1395. DOI: 10.3760/cma.j.issn.1007-1245.2023.10.013
Abstract
ObjectiveTo study the efficacy of Fufang Danshen Diwan combined with clopidogrel in the treatment of outpatients with coronary heart disease.
MethodsA total of 122 outpatients with coronary heart disease admitted to Jinan Second People's Hospital from January 2018 to November 2020 were selected as the research objects for the prospective study. According to the random number table method, they were divided into a combination group and a control group, with 61 cases in each group. There were 30 males and 31 females in the control group; they were 32-81 (55.67±7.21) years old. There were 31 males and 30 females in the combination group; they were 39-76 years old. The control group were treated with clopidogrel, and the combination group with clopidogrel and Fufang Danshen Diwan. The clinical efficacies and platelet function [platelet membrane glycoprotein GpⅡb /Ⅲa complex (PAC-1) and maximum platelet aggregation rate] and coagulation function [D-dimer (D-D) and antithrombin Ⅲ (AT-Ⅲ)] before and one month after the treatment were evaluated. The data were compared between these two groups by t and χ2 tests and rank-sum test.
ResultsBefore the treatment, there were no statistical differences in PAC-1 and maximum platelet aggregation rate between the two groups (both P>0.05). After the treatment, the PAC-1 and platelet maximum aggregation rates decreased in both group as compared with those before the treatment (all P<0.05); and those in the combined group was lower than those in the control group (both P<0.05). The clinical efficacy of the combined group was better than that of the control group [95.08% (58/61) vs. 77.05% (47/61)], with a statistical difference (P<0.05). After 1 month's treatment, the levels of D-D in the 2 groups were higher than those before the treatment (both P<0.05), and that in combination group was higher than that in control group (P<0.05); the AT-Ⅲ levels were lower than those before the treatment (both P<0.05), and that in the combination group was lower than that in the control group (P<0.05).
ConclusionFufang Danshen Diwan combined with clopidogrel in the treatment of outpatients with coronary heart disease can improve the therapeutic effect and their platelet function and coagulation function.
Key words:
Coronary heart disease; Outpatient department; Fufang Danshen Diwan; Platelet function; Platelet membrane glycoprotein; Clopidogrel; Platelet alpha-granular membrane glucoprotein
Contributor Information
Liu Ning
Clinic of General Medicine, Jinan Second People's Hospital, Jinan 250001, China
Jiang Lihua
Department of Internal Medicine, Jinan Second People's Hospital, Jinan 250001, China
Yin Chenghua
First Ward Division, Department of Cardiology, Jinan Second People's Hospital, Jinan 250001, China
